Flightpath Biosciences Australia

Flightpath Biosciences is a clinical-stage biotechnology company focused on developing novel therapeutics for infectious diseases, with a primary emphasis on Lyme disease. The company's lead candidate, FP-100 (hygromycin A), is a highly selective narrow-spectrum antibiotic designed to target Borrelia burgdorferi while preserving the natural gut microbiome. By focusing on pathogen-specific treatments, Flightpath aims to reduce the long-term complications associated with broad-spectrum antibiotic use, such as dysbiosis and persistent symptoms. The company is also exploring applications for its selective antibiotic platform in other spirochetal infections like syphilis.